(SNN) Smith & Nephew SNATS - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: US83175M2052
Stock: Implants, Repair, Wound Care, Surgical Tools
Total Rating 56
Risk 95
Buy Signal -0.18
| Risk 5d forecast | |
|---|---|
| Volatility | 27.1% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.56 |
| Alpha | 11.80 |
| Character TTM | |
|---|---|
| Beta | 0.231 |
| Beta Downside | 0.192 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.29% |
| CAGR/Max DD | 0.25 |
EPS (Earnings per Share)
Revenue
Description: SNN Smith & Nephew SNATS March 05, 2026
Smith & Nephew plc (SNN) develops and sells medical devices globally, with operations in the United Kingdom and United States.
The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. This structure reflects the diversified nature of the medical device industry.
SNNs product offerings include knee and hip implants, trauma and extremities products, and other reconstruction solutions. The orthopedic sector is a significant part of the medical device market due to an aging global population.
The Sports Medicine & ENT segment provides minimally invasive surgery tools, soft tissue injury treatments, and arthroscopic enabling technologies. Minimally invasive procedures are a growing trend in healthcare.
The Advanced Wound Management segment focuses on acute and chronic wound care, including bioactives and negative pressure wound therapy. Wound care is an essential component of post-operative recovery and chronic disease management.
SNN serves healthcare providers and was founded in 1856, headquartered in Watford, UK. Further research on ValueRay can provide more detailed financial and operational insights.
Headlines to watch out for
- Orthopaedics segment revenue growth drives overall company performance
- Sports Medicine & ENT product innovation expands market share
- Advanced Wound Management sales contribute to diversified revenue
- Regulatory approvals for new medical devices impact market entry
- Healthcare spending trends influence demand for elective procedures
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 1.04b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 10.56 > 1.0 |
| NWC/Revenue: 20.92% < 20% (prev 32.03%; Δ -11.11% < -1%) |
| CFO/TA 0.22 > 3% & CFO 2.28b > Net Income 1.04b |
| Net Debt (2.77b) to EBITDA (2.82b): 0.98 < 3 |
| Current Ratio: 2.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (436.5m) vs 12m ago -50.03% < -2% |
| Gross Margin: 68.80% > 18% (prev 0.70%; Δ 6.81k% > 0.5%) |
| Asset Turnover: 114.2% > 50% (prev 79.40%; Δ 34.78% > 0%) |
| Interest Coverage Ratio: 5.05 > 6 (EBITDA TTM 2.82b / Interest Expense TTM 329.4m) |
Altman Z'' 5.42
| A: 0.24 (Total Current Assets 4.10b - Total Current Liabilities 1.59b) / Total Assets 10.46b |
| B: 0.51 (Retained Earnings 5.32b / Total Assets 10.46b) |
| C: 0.16 (EBIT TTM 1.66b / Avg Total Assets 10.50b) |
| D: 1.07 (Book Value of Equity 5.52b / Total Liabilities 5.17b) |
| Altman-Z'' Score: 5.42 = AAA |
Beneish M -3.02
| DSRI: 0.74 (Receivables 1.43b/1.35b, Revenue 11.99b/8.37b) |
| GMI: 1.02 (GM 68.80% / 70.20%) |
| AQI: 1.02 (AQ_t 0.45 / AQ_t-1 0.44) |
| SGI: 1.43 (Revenue 11.99b / 8.37b) |
| TATA: -0.12 (NI 1.04b - CFO 2.28b) / TA 10.46b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of SNN shares?
As of March 18, 2026, the stock is trading at USD 33.37 with a total of 313,436 shares traded.
Over the past week, the price has changed by +0.91%, over one month by -6.58%, over three months by +2.55% and over the past year by +17.82%.
Over the past week, the price has changed by +0.91%, over one month by -6.58%, over three months by +2.55% and over the past year by +17.82%.
Is SNN a buy, sell or hold?
Smith & Nephew SNATS has received a consensus analysts rating of 3.75.
Therefor, it is recommend to hold SNN.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SNN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.6 | 9.7% |
| Analysts Target Price | 36.6 | 9.7% |
SNN Fundamental Data Overview March 14, 2026
P/E Trailing = 23.1049
P/E Forward = 12.7065
P/S = 2.2754
P/B = 2.6775
P/EG = 0.6691
Revenue TTM = 11.99b USD
EBIT TTM = 1.66b USD
EBITDA TTM = 2.82b USD
Long Term Debt = 3.15b USD (from longTermDebt, two quarters ago)
Short Term Debt = 150.0m USD (from shortTermDebt, last quarter)
Debt = 3.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.77b USD (from netDebt column, last quarter)
Enterprise Value = 16.80b USD (14.03b + Debt 3.33b - CCE 557.0m)
Interest Coverage Ratio = 5.05 (Ebit TTM 1.66b / Interest Expense TTM 329.4m)
EV/FCF = 11.50x (Enterprise Value 16.80b / FCF TTM 1.46b)
FCF Yield = 8.69% (FCF TTM 1.46b / Enterprise Value 16.80b)
FCF Margin = 12.18% (FCF TTM 1.46b / Revenue TTM 11.99b)
Net Margin = 8.66% (Net Income TTM 1.04b / Revenue TTM 11.99b)
Gross Margin = 68.80% ((Revenue TTM 11.99b - Cost of Revenue TTM 3.74b) / Revenue TTM)
Gross Margin QoQ = 65.56% (prev 70.62%)
Tobins Q-Ratio = 1.61 (Enterprise Value 16.80b / Total Assets 10.46b)
Interest Expense / Debt = 2.24% (Interest Expense 74.6m / Debt 3.33b)
Taxrate = 20.39% (84.7m / 415.6m)
NOPAT = 1.32b (EBIT 1.66b * (1 - 20.39%))
Current Ratio = 2.57 (Total Current Assets 4.10b / Total Current Liabilities 1.59b)
Debt / Equity = 0.63 (Debt 3.33b / totalStockholderEquity, last quarter 5.29b)
Debt / EBITDA = 0.98 (Net Debt 2.77b / EBITDA 2.82b)
Debt / FCF = 1.90 (Net Debt 2.77b / FCF TTM 1.46b)
Total Stockholder Equity = 5.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.89% (Net Income 1.04b / Total Assets 10.46b)
RoE = 19.51% (Net Income TTM 1.04b / Total Stockholder Equity 5.32b)
RoCE = 19.61% (EBIT 1.66b / Capital Employed (Equity 5.32b + L.T.Debt 3.15b))
RoIC = 15.36% (NOPAT 1.32b / Invested Capital 8.62b)
WACC = 5.81% (E(14.03b)/V(17.35b) * Re(6.77%) + D(3.33b)/V(17.35b) * Rd(2.24%) * (1-Tc(0.20)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -29.29%
[DCF] Terminal Value 88.43% ; FCFF base≈1.02b ; Y1≈1.26b ; Y5≈2.14b
[DCF] Fair Price = 140.4 (EV 62.36b - Net Debt 2.77b = Equity 59.59b / Shares 424.5m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 15.81 | EPS CAGR: 282.5% | SUE: -1.97 | # QB: 0
Revenue Correlation: 38.94 | Revenue CAGR: 5.62% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2.05 | Chg7d=+0.237 | Chg30d=+0.242 | Revisions Net=+0 | Growth EPS=+0.5% | Growth Revenue=+6.0%
EPS next Year (2027-12-31): EPS=2.09 | Chg7d=+0.287 | Chg30d=+0.287 | Revisions Net=+1 | Growth EPS=+2.0% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.6% (Discount Rate 7.9% - Earnings Yield 4.3%)
[Growth] Growth Spread = +2.0% (Analyst 5.6% - Implied 3.6%)
P/E Forward = 12.7065
P/S = 2.2754
P/B = 2.6775
P/EG = 0.6691
Revenue TTM = 11.99b USD
EBIT TTM = 1.66b USD
EBITDA TTM = 2.82b USD
Long Term Debt = 3.15b USD (from longTermDebt, two quarters ago)
Short Term Debt = 150.0m USD (from shortTermDebt, last quarter)
Debt = 3.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.77b USD (from netDebt column, last quarter)
Enterprise Value = 16.80b USD (14.03b + Debt 3.33b - CCE 557.0m)
Interest Coverage Ratio = 5.05 (Ebit TTM 1.66b / Interest Expense TTM 329.4m)
EV/FCF = 11.50x (Enterprise Value 16.80b / FCF TTM 1.46b)
FCF Yield = 8.69% (FCF TTM 1.46b / Enterprise Value 16.80b)
FCF Margin = 12.18% (FCF TTM 1.46b / Revenue TTM 11.99b)
Net Margin = 8.66% (Net Income TTM 1.04b / Revenue TTM 11.99b)
Gross Margin = 68.80% ((Revenue TTM 11.99b - Cost of Revenue TTM 3.74b) / Revenue TTM)
Gross Margin QoQ = 65.56% (prev 70.62%)
Tobins Q-Ratio = 1.61 (Enterprise Value 16.80b / Total Assets 10.46b)
Interest Expense / Debt = 2.24% (Interest Expense 74.6m / Debt 3.33b)
Taxrate = 20.39% (84.7m / 415.6m)
NOPAT = 1.32b (EBIT 1.66b * (1 - 20.39%))
Current Ratio = 2.57 (Total Current Assets 4.10b / Total Current Liabilities 1.59b)
Debt / Equity = 0.63 (Debt 3.33b / totalStockholderEquity, last quarter 5.29b)
Debt / EBITDA = 0.98 (Net Debt 2.77b / EBITDA 2.82b)
Debt / FCF = 1.90 (Net Debt 2.77b / FCF TTM 1.46b)
Total Stockholder Equity = 5.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.89% (Net Income 1.04b / Total Assets 10.46b)
RoE = 19.51% (Net Income TTM 1.04b / Total Stockholder Equity 5.32b)
RoCE = 19.61% (EBIT 1.66b / Capital Employed (Equity 5.32b + L.T.Debt 3.15b))
RoIC = 15.36% (NOPAT 1.32b / Invested Capital 8.62b)
WACC = 5.81% (E(14.03b)/V(17.35b) * Re(6.77%) + D(3.33b)/V(17.35b) * Rd(2.24%) * (1-Tc(0.20)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -29.29%
[DCF] Terminal Value 88.43% ; FCFF base≈1.02b ; Y1≈1.26b ; Y5≈2.14b
[DCF] Fair Price = 140.4 (EV 62.36b - Net Debt 2.77b = Equity 59.59b / Shares 424.5m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 15.81 | EPS CAGR: 282.5% | SUE: -1.97 | # QB: 0
Revenue Correlation: 38.94 | Revenue CAGR: 5.62% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2.05 | Chg7d=+0.237 | Chg30d=+0.242 | Revisions Net=+0 | Growth EPS=+0.5% | Growth Revenue=+6.0%
EPS next Year (2027-12-31): EPS=2.09 | Chg7d=+0.287 | Chg30d=+0.287 | Revisions Net=+1 | Growth EPS=+2.0% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.6% (Discount Rate 7.9% - Earnings Yield 4.3%)
[Growth] Growth Spread = +2.0% (Analyst 5.6% - Implied 3.6%)